JP3522865B2 - Urine leukocyte detection method - Google Patents
Urine leukocyte detection methodInfo
- Publication number
- JP3522865B2 JP3522865B2 JP31571394A JP31571394A JP3522865B2 JP 3522865 B2 JP3522865 B2 JP 3522865B2 JP 31571394 A JP31571394 A JP 31571394A JP 31571394 A JP31571394 A JP 31571394A JP 3522865 B2 JP3522865 B2 JP 3522865B2
- Authority
- JP
- Japan
- Prior art keywords
- urine
- concentration
- urinary
- leukocytes
- mpo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000265 leukocyte Anatomy 0.000 title claims description 79
- 210000002700 urine Anatomy 0.000 title description 71
- 238000001514 detection method Methods 0.000 title description 3
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 42
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 38
- 230000002485 urinary effect Effects 0.000 claims description 27
- 238000012360 testing method Methods 0.000 claims description 24
- 210000001635 urinary tract Anatomy 0.000 claims description 5
- 208000019206 urinary tract infection Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
- 206010064921 Urinary tract inflammation Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 210000000440 neutrophil Anatomy 0.000 description 13
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 108090000371 Esterases Proteins 0.000 description 10
- 239000013049 sediment Substances 0.000 description 9
- 108010063045 Lactoferrin Proteins 0.000 description 8
- 102000010445 Lactoferrin Human genes 0.000 description 8
- 235000021242 lactoferrin Nutrition 0.000 description 8
- 229940078795 lactoferrin Drugs 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 208000035404 Autolysis Diseases 0.000 description 6
- 206010057248 Cell death Diseases 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 201000008383 nephritis Diseases 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 230000028043 self proteolysis Effects 0.000 description 6
- 238000004820 blood count Methods 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000002753 trypsin inhibitor Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 229940122055 Serine protease inhibitor Drugs 0.000 description 3
- 101710102218 Serine protease inhibitor Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000003001 serine protease inhibitor Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 108010088854 urinastatin Proteins 0.000 description 3
- 108091005508 Acid proteases Proteins 0.000 description 2
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091005658 Basic proteases Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003028 enzyme activity measurement method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- IRTLROCMFSDSNF-UHFFFAOYSA-N 2-phenyl-1h-pyrrole Chemical compound C1=CNC(C=2C=CC=CC=2)=C1 IRTLROCMFSDSNF-UHFFFAOYSA-N 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 206010037597 Pyelonephritis acute Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 201000001555 acute pyelonephritis Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 238000006149 azo coupling reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- YAQKGZXXQNKEET-UHFFFAOYSA-N clazolam Chemical compound C1C(=O)N(C)C2=CC=C(Cl)C=C2C2C3=CC=CC=C3CCN21 YAQKGZXXQNKEET-UHFFFAOYSA-N 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229950008558 ulinastatin Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Description
【0001】[0001]
【産業上の利用分野】この発明は、尿中白血球の検出方
法に関し、特に、尿中ミエロペルオキシダーゼ濃度を測
定することによって、崩壊白血球も含めて検出できる尿
中白血球の検出方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for detecting leukocytes in urine, and more particularly to a method for detecting leukocytes in urine which can be detected including lysed leukocytes by measuring the concentration of myeloperoxidase in urine.
【0002】[0002]
【従来の技術】尿中白血球は、尿路感染症や尿路系炎症
性疾患における重要な指標であるが、従来は、もっぱら
尿沈渣鏡検法や試験紙法(エステラーゼ活性)によって
尿中白血球を測定してきた。この試験紙法は、基質とし
て、例えば、3−(N−トルエンスルホニル−L−アラ
ニロキシ)−5−フェニルピロールを用い、好中球エス
テラーゼによる加水分解物の1つである3−ヒドロキシ
−5−フェニルピロールを、1−ジアゾ−2−ナフトー
ル−4−スルホン酸とジアゾカップリングさせ、これに
より生成される物質が紫色を呈する反応を肉眼比色して
白血球尿の検査をするものである。Urine leukocytes are an important index in urinary tract infections and inflammatory diseases of the urinary tract. Conventionally, urinary leukocytes are exclusively examined by urinary sediment microscopy and test strip methods (esterase activity). Has been measured. This test strip method uses, for example, 3- (N-toluenesulfonyl-L-alaniryloxy) -5-phenylpyrrole as a substrate, and 3-hydroxy-5-one which is one of the hydrolysates by neutrophil esterase. Phenylpyrrole is subjected to diazo coupling with 1-diazo-2-naphthol-4-sulfonic acid, and the reaction of the substance produced by the reaction to give a purple color is visually compared to examine leukocyte urine.
【0003】[0003]
【発明が解決しようとする課題】しかしながら、本発明
者の研究によれば、沈渣鏡検法や試験紙法では、白血球
崩壊に因るものと推定される偽陰性例が少なからず存在
することが示唆された。すなわち、尿中白血球の95%
は好中球であることから、日常検体について、尿中好中
球由来蛋白濃度と、尿沈渣鏡検法や試験紙法による測定
結果とを比較したところ、図1、図2の結果が得られ、
偽陰性例の存在が示唆された。なお、好中球由来蛋白と
して、特殊顆粒内に存在するラクトフェリン(Lf)
と、アズール顆粒内に存在するミエロペルオキシダーゼ
(MPO)に着目した。図1において、尿沈渣白血球数
は、日本臨床衛生検査技師会の定める尿沈渣標本の作製
法に準じて標本を作製して鏡検した。また、図2(及
び、それ以降)の測定において、尿試験紙はAM社、B
M社のものを用いた。一方、図1〜図2における尿中好
中球由来蛋白については、抗ヒトポリクローナル抗体を
用いてELISA法によって測定した。具体的には、
(1) 各蛋白に対するポリクローナル抗体を固定したマイ
プロプレートのウエルに、終濃度0.05%の界面活性
剤(TritonX100)を含む尿試料を50μlサンプリング
する。(2) 37℃で1時間インキュベーションした後、
純水洗浄し、マイクロプレートのウエルに2.5μl/
mlの濃度に希釈したアルカリホスファターゼ(AL
P)標識抗体を100μl分注する。(3) 37℃で1時
間インキュベーションした後、純水洗浄して、KIND
−KING法ALP基質を100μl分注する。(4) 3
7℃で30分間インキュベーションした後、ALP発色
液を100μl分注し、510/630nmで測光し
て、各蛋白(ラクトフェリン、ミエロペルオキシダー
ゼ)の濃度を算出した。図1〜図2より明らかなよう
に、尿沈渣白血球数が10/HPF以下の群や、試験紙
法における−±群の白血球少数群において、MPOやL
fの高値を示す不一致例が認められ、沈渣鏡検法及び試
験紙法とも、白血球崩壊による偽陰性例の存在が示唆さ
れる。この発明は、この問題点に着目してなされたもの
であって、より確実に尿中白血球を検出できる尿中白血
球検出方法を提供することを目的とする。However, according to the study by the present inventor, there are not a few false-negative cases presumed to be due to leukolysis in the sediment microscopy and test strip methods. It was suggested. That is, 95% of white blood cells in urine
Is a neutrophil, the urinary neutrophil-derived protein concentration in daily samples was compared with the measurement results by urinary sediment microscopy and test strip methods, and the results in Figs. 1 and 2 were obtained. The
The presence of false negative cases was suggested. As a neutrophil-derived protein, lactoferrin (Lf) present in special granules
Attention was paid to myeloperoxidase (MPO) present in azure granules. In FIG. 1, the urinary sediment white blood cell count was microscopically examined by preparing a sample according to the method for preparing a urinary sediment sample defined by the Japan Society for Clinical Hygiene Inspection. In addition, in the measurement of FIG. 2 (and later), the urine test strip is AM company, B
The one manufactured by M Co. was used. On the other hand, the urinary neutrophil-derived protein in FIGS. 1 and 2 was measured by an ELISA method using an anti-human polyclonal antibody. In particular,
(1) 50 μl of a urine sample containing a surfactant (Triton X100) at a final concentration of 0.05% is sampled in the well of a Mypro plate on which polyclonal antibodies against each protein are fixed. (2) After incubating at 37 ℃ for 1 hour,
Wash with pure water and add 2.5 μl / well to the well of the microplate.
Alkaline phosphatase (AL
P) Dispense 100 μl of the labeled antibody. (3) Incubate at 37 ℃ for 1 hour, wash with pure water, and then KIND
Dispense 100 μl of KING method ALP substrate. (4) 3
After incubating at 7 ° C. for 30 minutes, 100 μl of the ALP color development solution was dispensed and photometry was performed at 510/630 nm to calculate the concentration of each protein (lactoferrin, myeloperoxidase). As is clear from FIGS. 1 and 2, MPO and L
There were discordant cases showing high f values, suggesting the presence of false negative cases due to leukolysis in both sedimentoscopy and test strip methods. The present invention has been made in view of this problem, and an object of the present invention is to provide a urine leukocyte detection method capable of detecting urine leukocytes more reliably.
【0004】[0004]
【課題を解決するための手段】上記の目的を達成するた
め、本発明では、尿中ミエロペルオキシダーゼ濃度を測
定することによって尿中白血球を検出している。また、
尿中ミエロペルオキシダーゼ濃度と尿中ラクトフェリン
濃度とを測定して、尿中ミエロペルオキシダーゼ濃度が
低値で尿中ラクトフェリン濃度のみが高値であることを
指標にすれば、初期段階の腎炎を検出することもでき
る。以下、本発明の完成に至るまでの検討内容を説明し
つつ、本発明の効果についても説明する。In order to achieve the above object, in the present invention, leukocytes in urine are detected by measuring the concentration of myeloperoxidase in urine. Also,
By measuring the urinary myeloperoxidase concentration and the urinary lactoferrin concentration and using the low urine myeloperoxidase concentration and the high urinary lactoferrin concentration alone as indicators, it is possible to detect nephritis in the early stage. it can. Hereinafter, the effects of the present invention will be described while describing the contents of the study until the completion of the present invention.
【0005】〔尿中白血球数測定法(沈渣鏡検法、計算
盤法)の問題点〕図1、図2の結果を踏まえて、本発明
者は、先ず、尿中の白血球細胞が崩壊する実態について
検討を加えた。図3は、日常検体75例の尿試料につい
ての白血球崩壊率の分布を図示したものである。具体的
には、遠沈により細胞成分を除いた上清に白血球を30
00〜4000個/μl加え、37℃で15時間放置し
てコールターSTKS(自動血球計測装置)で計測して
崩壊率(%)を求めたものである。なお、好中球約60
%、リンパ球約40%の白血球を用いたが、崩壊率の平
均値は33.3%(最小0.0%、最大93.8%)で
あった。従来より、尿中白血球の崩壊には、尿浸透圧と
尿pHが関係していると指摘されているので、次に、前
記の日常検体について、尿浸透圧と尿pHとを測定し
た。なお、尿浸透圧は、京都第一科学の尿浸透圧測定器
(OM−6010)を用いた。尿浸透圧及び尿pHと白
血球崩壊率との関係は、図4(a)(b)の通りであ
り、尿浸透圧と白血球崩壊率との間には特別な関係が認
められないが、尿中白血球崩壊率は、尿pHが5〜6に
おいて約20%認められ、アルカリ度が増すに従って崩
壊率が急速に高まることが明らかとなった。[Problems of urinary leukocyte count method (sedimentoscopy method, counting method)] Based on the results of FIGS. 1 and 2, the present inventor firstly disrupts white blood cells in urine. We examined the actual situation. FIG. 3 is a diagram showing the distribution of leukocyte disintegration rates for urine samples of 75 daily samples. Specifically, 30 leukocytes were added to the supernatant obtained by removing the cell components by centrifugation.
The disintegration rate (%) was obtained by adding 00 to 4000 cells / μl, allowing to stand at 37 ° C. for 15 hours, and measuring with a Coulter STKS (automatic blood cell counter). In addition, about 60 neutrophils
%, Lymphocytes of about 40% were used, but the average value of the disintegration rate was 33.3% (minimum 0.0%, maximum 93.8%). Conventionally, it has been pointed out that urine osmotic pressure and urine pH are related to the breakdown of leukocytes in urine. Next, the urine osmotic pressure and urine pH of the above-mentioned daily samples were measured. In addition, the urine osmotic pressure used the urine osmotic pressure measuring device (OM-6010) of Kyoto Daiichi Scientific. The relationship between the urine osmotic pressure and the urine pH and the leukocyte disintegration rate is as shown in FIGS. 4 (a) and 4 (b). Although there is no special relationship between the urine osmotic pressure and the leukocyte disintegration rate, The middle leukocyte disintegration rate was about 20% when the urine pH was 5 to 6, and it was revealed that the disintegration rate rapidly increases as the alkalinity increases.
【0006】次に、白血球崩壊に関わる因子を特定する
べく、放置時間と白血球崩壊率の関係、放置温度と白血
球崩壊率の関係、pHと白血球崩壊率の関係を調べた。
図5(a)は、pH7.5の尿試料に対して図3の場合
と同様に白血球を加えて、37℃で25時間放置した場
合の崩壊率の時間的推移を図示したものであり、図5
(b)は、ある尿試料を3分して図3の場合と同様に白
血球を加えた後、4℃、25℃、37℃で15時間放置
した場合の白血球崩壊率の違いを比較したものである。
また、図5(c)は、同一の尿試料(プール尿)につい
て、HClまたはNaOHを用いてpHを調整して、3
7℃で15時間放置後の白血球崩壊率の違いを図示した
ものである。図5の結果によれば、pH9程度のアルカ
リ尿は崩壊が特に激しく、尿中白血球の崩壊には酵素が
関与していることが示唆されている。但し、酸性尿でも
25%程度の崩壊が生じている。Next, in order to identify the factors involved in leukocyte lysis, the relationship between the standing time and leukocyte lysis rate, the relationship between standing temperature and leukocyte lysis rate, and the relationship between pH and leukocyte lysis rate were investigated.
FIG. 5 (a) shows the time course of the disintegration rate when white blood cells were added to a urine sample having a pH of 7.5 as in the case of FIG. 3 and left at 37 ° C. for 25 hours. Figure 5
(B) is a comparison of the leukolysis rate when a certain urine sample was divided into 3 minutes and leukocytes were added in the same manner as in FIG. 3 and then left at 4 ° C., 25 ° C. and 37 ° C. for 15 hours. Is.
Further, FIG. 5 (c) shows that the same urine sample (pool urine) was adjusted to pH 3 with HCl or NaOH.
It is a diagram showing the difference in the leukolysis rate after standing for 15 hours at 7 ° C. The results shown in FIG. 5 suggest that alkaline urine having a pH of about 9 is particularly strongly disintegrated, and that enzymes are involved in the disintegration of leukocytes in urine. However, even about 25% of acid urine is disintegrated.
【0007】そこで次に、pH値の異なる0.15mo
lのリン酸緩衝液に、それぞれ白血球を3000〜40
00個/μl加え、更に、酸プロテアーゼまたはアルカ
リプロテアーゼを50単位/ml加えて、37℃で15
時間放置して、pH値による白血球崩壊率の相違を調べ
た(図6(a))。また、pH値の異なる0.15mo
lのリン酸緩衝液に白血球を3000〜4000個/μ
l加え、37℃で15時間放置して、自己融解による白
血球崩壊を調べた(図6(b))。図6(a)(b)の
結果より、尿pH酸性側での白血球崩壊は、主に細菌由
来の酸プロテアーゼによるものと考えられ、一方、尿p
Hアルカリ側での白血球崩壊は、白血球内のプロテアー
ゼによる自己融解と、細菌由来のアルカリプロテアーゼ
の作用によるものと考えられる。Therefore, next, 0.15 mo having different pH values is used.
leukocytes were added to each of the phosphate buffers of 1 to 3000-40
Add 00 units / μl, and then add 50 units / ml of acid protease or alkaline protease at 15 ℃ at 37 ℃.
After allowing to stand for a period of time, the difference in leukocyte disintegration rate depending on the pH value was examined (FIG. 6 (a)). In addition, 0.15mo with different pH values
White blood cells 3000-4000 / μ in 1 l phosphate buffer
1 was added, and the mixture was allowed to stand at 37 ° C. for 15 hours, and leukolysis caused by autolysis was examined (FIG. 6 (b)). From the results of FIGS. 6 (a) and 6 (b), it is considered that the leukocyte disintegration on the acidic side of urine pH is mainly due to the acid protease derived from bacteria.
Leukocyte disintegration on the H-alkaline side is considered to be due to autolysis by protease in leukocytes and the action of bacterial alkaline protease.
【0008】図7(a)は、細胞成分を除いた尿試料の
上清に白血球3000〜4000個/μlを加えたもの
に、それぞれ別の阻害剤を添加して、37℃15時間後
の尿中白血球数を求めて尿中白血球崩壊阻止率を算出し
たものである。添加する阻害剤は、EDTA(10mm
ol)、ABSF(1mmol)、EDTA(10mm
ol)+ABSF(1mmol)であり、ABSFと
は、セリンプロテアーゼインヒビター〔4−(2−Amin
oethyl)benzensulfonyl Fluoride Hydrochloride 〕で
ある。尿中白血球崩壊現象が主に酵素の作用によるが故
に、図7(a)に示す通り、酵素阻害剤によって尿中白
血球崩壊を阻止できたものと考えられる。特に、セリン
プロテアーゼインヒビターと金属プロテアーゼ阻害剤で
あるEDTAとの併用が有効であった。FIG. 7 (a) shows that urine sample supernatant from which cell components have been removed, to which 3000 to 4000 leukocytes / μl have been added, and another inhibitor has been added, respectively, at 37 ° C. for 15 hours. The urinary leukocyte collapse inhibition rate was calculated by obtaining the urine leukocyte count. The inhibitor added is EDTA (10 mm
ol), ABSF (1 mmol), EDTA (10 mm
ol) + ABSF (1 mmol), and ABSF is a serine protease inhibitor [4- (2-Amin
oethyl) benzensulfonyl Fluoride Hydrochloride]. It is considered that the urinary leukocyte destruction was prevented by the enzyme inhibitor, as shown in FIG. 7 (a), because the urinary leukolysis phenomenon was mainly due to the action of the enzyme. In particular, the combined use of serine protease inhibitor and EDTA which is a metalloprotease inhibitor was effective.
【0009】図7(b)は、pH5〜9に調整した0.
15molのリン酸緩衝液に白血球を3000〜400
0個/μl加えたものに阻害剤を添加して37℃15時
間放置して、細菌が存在しない状態での自己融解による
白血球崩壊を調べたものである。阻害剤としては、ED
TA(10mmol)、ABSF(1mmol)、α1
−アンチトリプシン(300mg/dl)を用いて、白
血球自己融解の阻止率を求めた。図7(b)の結果によ
れば、白血球自己融解の阻止には、白血球内のセリンプ
ロテアーゼに対する阻害剤としてのα1−アンチトリプ
シンは無効であり、低分子のセリンプロテアーゼインヒ
ビターが著効であることが明らかとなった。以上より、
自己融解による白血球崩壊を阻止するには、白血球内に
入って作用可能な阻害剤が有効であると考えられるが、
尿中白血球は、排尿以前にも酵素の作用によって崩壊す
るのであるから、単に尿中白血球数をカウントするだけ
では尿路感染症や尿路系炎症性疾患を見落とす恐れがあ
ると考えられる。FIG. 7 (b) shows that the pH value is adjusted to pH 5-9.
Leukocytes were added to 15 to 30 mol of phosphate buffer solution for 3000 to 400
Inhibitors were added to 0 cells / μl and left at 37 ° C. for 15 hours, and leukocyte disintegration due to autolysis in the absence of bacteria was examined. As an inhibitor, ED
TA (10 mmol), ABSF (1 mmol), α1
-The inhibition rate of leukocyte autolysis was determined using antitrypsin (300 mg / dl). According to the results of FIG. 7 (b), α1-antitrypsin as an inhibitor against serine protease in leukocytes is ineffective in inhibiting leukocyte autolysis, and a low-molecular-weight serine protease inhibitor is significantly effective. Became clear. From the above,
Inhibitors that can act by entering leukocytes are considered to be effective in preventing leukocyte breakdown due to autolysis.
Since urinary leukocytes are destroyed by the action of an enzyme before urination, it is considered that urinary tract infections and urinary tract inflammatory diseases may be overlooked by simply counting the number of urinary leukocytes.
【0010】〔試験紙法(酵素活性測定法)の問題点〕
次に、試験紙法で陰性でありながら好中球由来蛋白では
陽性を示した図2の不一致尿について更に検討した。遠
沈により細胞成分を除いた上清に、白血球500個/μ
lを添加して試験紙法で調べたところ、前記の不一致尿
(NO.1〜NO.5)は、正常尿に白血球500個/μlを添
加したコントロールに比べて、種々の程度にエステラー
ゼ活性の阻害が認められた(図8)。そこで、エステラ
ーゼ活性を阻害する尿中成分の分子量を推定するべく、
不一致尿を生理的食塩水で透析してみたところ、エステ
ラーゼ阻害物質が高分子であることが明らかとなった。
次いで、ゲル濾過(セファクリル100)を行い、各フ
ラクションに白血球500個/μlを添加して試験紙法
でエステラーゼ活性を測定したところ図9の結果が得ら
れた。図9に示す通り、分子量約60,000の画分に
エステラーゼ活性阻害物質の存在が認められた。[Problems of Test Paper Method (Enzyme Activity Measurement Method)]
Next, the discordant urine shown in FIG. 2, which was negative in the test strip method but positive in the neutrophil-derived protein, was further examined. The supernatant from which cell components were removed by centrifugation was added with 500 leukocytes / μ
When the test paper method was carried out by adding l, the above-mentioned inconsistent urine (NO.1 to NO.5) showed various levels of esterase activity as compared with the control in which 500 leukocytes / μl were added to normal urine. Inhibition was observed (Fig. 8). Therefore, in order to estimate the molecular weight of urinary components that inhibit esterase activity,
Dialysis of inconsistent urine against physiological saline revealed that the esterase inhibitor was a polymer.
Then, gel filtration (Sephacryl 100) was performed, and 500 leukocytes / μl were added to each fraction and the esterase activity was measured by the test paper method. The results shown in FIG. 9 were obtained. As shown in FIG. 9, the presence of an esterase activity inhibitor was observed in the fraction having a molecular weight of about 60,000.
【0011】血清に白血球を500個/μl添加したも
のについて試験紙法で調べると全く反応せず(図10
(e))、血清を2倍、4倍と希釈するに応じて幾らか
反応することより(図10(f)(g))、試験紙法に
対する阻害物質は、血清中にも存在することが確認され
る。そして、プロテアーゼのうちトリプシンなどアミノ
酸またはペプチドのエステルを加水分解するものは、エ
ステラーゼ活性を持つことが知られていることから、阻
害物質としてトリプシン阻害物質の関与が考えられる。
そこで、生理的食塩水に白血球500個/μlを添加し
たものに、α1−アンチトリプシン、α1−アンチキモ
トリプシン、ウリナスタチンをそれぞれ作用させて試験
紙法による反応を調べたところ、図10(b)(c)
(d)の結果が得られた。この結果より、阻害物質はα
1−アンチトリプシン、α1−アンチキモトリプシンで
はなく、健常者尿中にも存在するウリナスタンチン(分
子量約60,000)を始めとする尿中トリプシン阻害
物質の可能性が高いと結論される。When blood cells were added with 500 leukocytes / μl, the test paper method revealed no reaction (Fig. 10).
(E)), since the serum reacts somewhat with dilution to 2-fold or 4-fold (FIGS. 10 (f) and (g)), the inhibitor for the test strip method is also present in serum. Is confirmed. It is known that proteases that hydrolyze amino acid or peptide esters such as trypsin have esterase activity, and therefore involvement of trypsin inhibitors as inhibitors is considered.
Therefore, when α1-antitrypsin, α1-antichymotrypsin, and ulinastatin were allowed to act on physiological saline to which 500 leukocytes / μl had been added, and the reaction was examined by the test strip method, FIG. 10 (b) ( c)
The result of (d) was obtained. From this result, the inhibitor is α
It is concluded that there is a high possibility that the urinary trypsin inhibitor is not 1-antitrypsin or α1-antichymotrypsin, but urinastantin (molecular weight of about 60,000) that is also present in the urine of healthy subjects.
【0012】細胞の状態にある白血球と、崩壊された状
態の白血球とでは、試験紙法の反応が違うであろうと予
想されるので、阻害物質を高濃度含む図2の不一致尿に
ついて、超音波処理を施した白血球500個/μlを不
一致尿の上清に加えた場合と、無処理の白血球500個
/μlを加えた場合について、試験紙法の反応特性を調
べてみた。その結果は、図11の通りであり、不一致尿
において、崩壊白血球由来のエステラーゼは活性を示さ
ないが(図11の左欄)、白血球内のエステラーゼ活性
は、試験紙上で崩壊するため完全には阻害されることが
少ない(図11の右欄)ことが明らかとなった。試験紙
法による結果が、尿沈渣中白血球数と比較的一致するの
は、このためであると考えられる。Since it is expected that the reaction of the test strip method will be different between the leukocytes in the state of cells and the leukocytes in the state of disintegration, ultrasonic waves were detected for the inconsistent urine in FIG. 2 containing a high concentration of the inhibitor. The reaction characteristics of the test strip method were examined for the case where 500 leukocytes / μl treated were added to the supernatant of the inconsistent urine and the case where 500 leukocytes / μl untreated were added. The results are as shown in FIG. 11, and in the inconsistent urine, the esterase derived from the disrupted leukocytes does not show activity (left column in FIG. 11), but the esterase activity in the leukocytes is completely disintegrated on the test paper. It was revealed that there was little inhibition (right column of FIG. 11). It is considered that this is the reason why the results obtained by the test strip method are relatively consistent with the white blood cell count in the urine sediment.
【0013】〔本発明の有効性〕以上の通り、沈渣鏡検
法には白血球崩壊の問題があり、試験紙法には尿中トリ
プシン阻害物質の問題があることが明らかとなった。そ
こで、ラクトフェリンLfやミエロペルオキシダーゼM
POによる尿中白血球検出の有効性について次に検討し
た。図12(a)の相関図は、無作為に選択した尿試料
(日常検体)について、ミエロペルオキシダーゼMPO
濃度とラクトフェリンLf濃度の相関を示したものであ
る。図12(a)の結果によれば、MPO濃度とLf濃
度が相関を示す群と、Lf濃度のみ高値を示す群とが認
められる。そして、Lf濃度のみ高値を示す群には、尿
中に10/HPF以上の白血球が存在する例は認められ
なかった。[Effectiveness of the Present Invention] As described above, it has been clarified that the sedimentoscopy method has a problem of leukolysis and the test strip method has a problem of urinary trypsin inhibitor. Therefore, lactoferrin Lf and myeloperoxidase M
Next, the effectiveness of urinary leukocyte detection by PO was examined. The correlation diagram of FIG. 12 (a) shows that myeloperoxidase MPO was obtained for randomly selected urine samples (daily samples).
It shows the correlation between the concentration and the lactoferrin Lf concentration. According to the result of FIG. 12A, a group in which the MPO concentration and the Lf concentration have a correlation and a group in which only the Lf concentration has a high value are recognized. In the group showing a high Lf concentration alone, no example was observed in which urine contained 10 / HPF or more leukocytes.
【0014】次に、MPO濃度、Lf濃度ともに低値を
示す尿試料に対して、白血球を1個〜1000個/μl
添加したところ、両蛋白には良好な相関が認められた
(図12(b))。以上の結果より、図12(a)にお
いて、MPO濃度とLf濃度が相関を示す群は、白血球
数を反映したものと考えられ、一方、Lf濃度のみ高値
を示す群は、白血球が無いのにLf濃度のみが非常に高
濃度となる何か別の原因があるものと考えられる。図1
3は、MPOの尿中での安定性と添加回収率を示したも
のである。図13(a)に示す通り、尿中MPOは、3
7℃で24時間放置した後も残存率95%以上を示して
いる。また、図13(b)に示す通り、平均回収率は9
6.3%であり、沈渣鏡検法や試験紙法に見られる細胞
崩壊や酵素活性阻害による偽陰性の可能性は殆ど無いと
考えられる。Next, 1 to 1000 leukocytes / μl are added to the urine sample showing low MPO concentration and Lf concentration.
When added, a good correlation was observed between both proteins (Fig. 12 (b)). From the above results, in FIG. 12A, it is considered that the group in which the MPO concentration and the Lf concentration have a correlation reflects the white blood cell count, while the group in which only the Lf concentration has a high value has no leukocytes. It is considered that there is some other cause that only the Lf concentration becomes extremely high. Figure 1
3 shows the stability of MPO in urine and the addition recovery rate. As shown in FIG. 13 (a), MPO in urine was 3
The residual rate is 95% or more even after standing at 7 ° C. for 24 hours. Further, as shown in FIG. 13B, the average recovery rate is 9
The rate is 6.3%, and it is considered that there is almost no possibility of false negatives due to cell disruption and enzyme activity inhibition observed in the sediment microscopy and test strip methods.
【0015】図14(a)は、尿路に感染などの異常が
少ないと考えられる小学4年以下の640例(学齢以下
400例、小学1・2年生120例、小学3・4年生1
20例)について尿中MPO値を求めたものである。そ
の結果は、80±200ng/ml(mean±2SD)であ
り、カットオフ値は250ng/mlとした。なお、M
PO値の測定は、次のELISA法による。(1) 抗ヒト
ミエロペルオキシダーゼに対するポリクローナル抗体を
固定したマイプロプレートのウエルに、終濃度0.05
%の界面活性剤(TritonX100)を含む尿試料を50μl
サンプリングする。(2) 37℃で1時間インキュベーシ
ョンした後、純水洗浄し、マイクロプレートのウエルに
2.5μl/mlの濃度に希釈したアルカリホスファタ
ーゼ(ALP)標識抗体を100μl分注する。(3) 3
7℃で1時間インキュベーションした後、純水洗浄し
て、KIND−KING法ALP基質を100μl分注
する。(4) 37℃で30分間インキュベーションした
後、ALP発色液を100μl分注し、510/630
nmで測光して、ミエロペルオキシダーゼMPOの濃度
を算出する。FIG. 14 (a) shows 640 cases of elementary school 4 years or younger (400 cases of school age or younger, 120 cases of elementary school 1.2 years, 1 year of elementary school 3.4 years), which are considered to have few abnormalities in the urinary tract.
Urine MPO values were obtained for 20 cases). The result was 80 ± 200 ng / ml (mean ± 2SD), and the cutoff value was 250 ng / ml. In addition, M
The PO value is measured by the following ELISA method. (1) The final concentration of 0.05 was added to the wells of the Mypro plate on which the polyclonal antibody against anti-human myeloperoxidase was immobilized.
50 μl of urine sample containing 10% surfactant (TritonX100)
To sample. (2) After incubating at 37 ° C. for 1 hour, the plate is washed with pure water, and 100 μl of an alkaline phosphatase (ALP) -labeled antibody diluted to a concentration of 2.5 μl / ml is poured into the well of the microplate. (3) 3
After incubating at 7 ° C. for 1 hour, the mixture is washed with pure water and 100 μl of KIND-KING method ALP substrate is dispensed. (4) After incubating at 37 ° C for 30 minutes, 100 μl of ALP color development solution was added to 510/630.
The concentration of myeloperoxidase MPO is calculated by photometry at nm.
【0016】次に、尿中好中球数とMPO濃度の関係を
求めると図15の結果が得られた。すなわち、界面活性
剤(TritonX100)を終濃度0.05%含む生理的食塩水に
白血球を300個/μlまで適量添加し、界面活性剤を
含む生理的食塩水で倍々希釈を行った後、ELISA法
によってミエロペルオキシダーゼ濃度を測定して白血球
数との関係を求めた。図15の結果によれば、MPOカ
ットオフ値250ng/mlに相当する白血球数は約1
00個/μlであった。試験紙法のカットオフ値が10
〜30個/μl、これに相当する沈渣鏡検法の5〜15
個/HPFに比べて約3倍増である。この結果からも、
尿中では多数の白血球がすでに崩壊していることが示唆
され、尿中の白血球検出方法としては、崩壊白血球も測
定可能な本発明が好ましいことの証明ともなる。Next, when the relationship between the number of neutrophils in urine and the MPO concentration was determined, the results shown in FIG. 15 were obtained. That is, an appropriate amount of white blood cells was added to physiological saline containing a final concentration of 0.05% of a surfactant (Triton X100) up to 300 cells / μl, and the mixture was double-diluted with a physiological saline containing a surfactant, followed by ELISA. The myeloperoxidase concentration was measured by the method to determine the relationship with the white blood cell count. According to the result of FIG. 15, the number of white blood cells corresponding to the MPO cutoff value of 250 ng / ml is about 1.
The number was 00 / μl. Cutoff value of test paper method is 10
~ 30 / μl, equivalent to 5-15 of sediment microscopy
This is about a three-fold increase compared to individual / HPF. From this result,
It is suggested that a large number of leukocytes have already been disrupted in urine, which also proves that the present invention is preferable as a method for detecting leukocytes in urine, which is capable of measuring disrupted leukocytes.
【0017】〔尿中Lf濃度のみが高値であることの検
討〕次に、図12(a)において、白血球が存在しない
のにLf濃度のみが非常に高濃度となる群について検討
した。炎症細胞が主体となる溶連菌感染後の急性糸球体
腎炎や馬杉腎炎、あるいは急性腎盂腎炎では、好中球が
免疫複合体などにより活性化され、活性酸素を細胞外に
放出し、腎臓を傷害すると言われている。また、好中球
のMPOは、H2 O2とハロゲン(塩素、ヨウ素など)
からHOClやHOIなど細菌膜と反応しやすい強力な
活性酸素をつくる。このMPOは塩基性蛋白であるた
め、糸球体基底膜に豊富にある酸性なヒアルロン酸(血
液から蛋白質を尿中に出さないように働いている)に付
着し、そこにH2 O2 が存在すると蛋白尿が出現するこ
とが報告されている。[Study that only Lf concentration in urine is high] Next, in FIG. 12 (a), a group was examined in which only Lf concentration was extremely high even though there were no leukocytes. In acute glomerulonephritis, horse cedar nephritis, or acute pyelonephritis after streptococcal infection mainly composed of inflammatory cells, neutrophils are activated by immune complexes and the like, releasing active oxygen to the outside of the cell and damaging the kidneys. It is said. Also, MPO of neutrophils consists of H 2 O 2 and halogens (chlorine, iodine, etc.)
Produces strong active oxygen such as HOCl or HOI that easily reacts with bacterial membranes. Since this MPO is a basic protein, it attaches to the acidic hyaluronic acid (which works to prevent the protein from being released from the blood into the urine), which is abundant in the glomerular basement membrane, and H 2 O 2 is present there. Then, it has been reported that proteinuria appears.
【0018】また、学校集団検尿で発見される腎炎の発
症年齢は、80%の症例で11〜15才であると言われ
ているが、本発明者の研究でも同様の結果が得られてお
り、小学4年生(10才)以下ではラクトフェリンのみ
高値を示す例は存在しなかった(図16)。なお、図1
7は、図16に示す1360例について、小学5年生以
上と小学4年生以下の2群にまとめたものであり、Lf
が300ng/ml以上であって、MPO/LFが0.
2以下を示す症例は、40例(40/1360=2.9
%)認められる。腎炎にともなってトランスフェリン
(Tf)が最も早期に出現すると言われているので、次
に、(a)小学4年以下であって、Lf,MPOが50
ng/ml以下の428例、(b)小学5年以上であっ
て、Lf,MPOが50ng/ml以下の320例、
(c)小学5年以上であってLfのみ高値であった40
例(Lfが300ng/ml以上でMPO/LFが0.
2未満)の3群について、Tf濃度とLf濃度とを調べ
てみた。The onset age of nephritis found by school mass urinalysis is said to be 11 to 15 years in 80% of cases, but similar results were obtained in the study by the present inventor. In the 4th grade (10 years old and younger), there was no case in which only lactoferrin showed a high value (FIG. 16). Note that FIG.
Fig. 7 is a summary of the 1360 cases shown in Fig. 16 into two groups of 5th grade and above and 4th grade and below.
Of 300 ng / ml or more and MPO / LF of 0.
40 cases (40/1360 = 2.9)
%)Is recognized. Since it is said that transferrin (Tf) appears at the earliest stage with nephritis, next, (a) elementary school 4 years or older, Lf, MPO 50
428 cases of ng / ml or less, (b) 320 cases of 5 years or more in elementary school and Lf and MPO of 50 ng / ml or less,
(C) Elementary school 5 years or older and only Lf was high 40
Example (MPO / LF is 0..Lf when Lf is 300 ng / ml or more.
Tf concentration and Lf concentration were examined for 3 groups (less than 2).
【0019】図18は、その結果を示すものであり、ど
の群においてもLf濃度とTf濃度は無相関であり、図
18(c)の群でも、Tf濃度が高くないことが明らか
となった。なお、図19は、図18(a)(b)(c)
の3群について、Tf濃度の平均値やt検定結果などを
示したものであり、3群における尿中トランクフェリン
濃度間に有意差はなく、Lf≧300ng/ml,MP
O/LF<0.2の群においても、蛋白尿が出現してい
ないと考えられる。以上の諸点に鑑みると、Lf≧30
0ng/ml,MPO/LF<0.2の図18(c)の
群、つまり、図12(a)においてLf濃度のみ高値を
示す群は、蛋白が尿に漏れる以前の初期段階の腎炎の状
態を反映していると考えられる。従って、尿中MPO濃
度と尿中Lf濃度とを測定して、尿中Lf濃度のみ高値
を示す場合には、初期段階の腎炎の可能性が推定され
る。FIG. 18 shows the results, and it was clarified that the Lf concentration and the Tf concentration are uncorrelated in any of the groups, and that the Tf concentration is not high even in the group of FIG. 18 (c). . Note that FIG. 19 is similar to FIG. 18 (a) (b) (c).
3 shows the average value of Tf concentration and t-test result, etc., and there was no significant difference between the urinary trunk ferrin concentrations in the 3 groups, Lf ≧ 300 ng / ml, MP
It is considered that proteinuria did not appear even in the group of O / LF <0.2. Considering the above points, Lf ≧ 30
The group of FIG. 18 (c) in which 0 ng / ml and MPO / LF <0.2, that is, the group in which only the Lf concentration is high in FIG. 12 (a), is in the initial stage of nephritis before the protein leaks into the urine. Is considered to reflect. Therefore, when the MPO concentration in urine and the Lf concentration in urine are measured and only the Lf concentration in urine shows a high value, the possibility of nephritis in the initial stage is estimated.
【0020】[0020]
【発明の効果】以上説明したように、この発明では、尿
中ミエロペルオキシダーゼ濃度を測定することによって
尿中白血球を検出している。細胞数算定法は尿中白血球
の崩壊が激しいため偽陰性になりやすく、また酵素活性
測定法は、尿中トリプシン阻害物質により阻害を受ける
が、ミエロペルオキシダーゼ蛋白量の測定は、尿中の安
定に優れ、阻害物質の影響も少なく、崩壊白血球まで検
出できるという優れた効果を発揮する。As described above, in the present invention, leukocytes in urine are detected by measuring the myeloperoxidase concentration in urine. The cell count method is prone to false negatives because urinary leukocyte breakdown is severe, and the enzyme activity measurement method is inhibited by urinary trypsin inhibitors, but the myeloperoxidase protein level is stable in urine. It is excellent, has little effect of inhibitors, and exerts an excellent effect of being able to detect even disrupted leukocytes.
【図1】尿中好中球由来蛋白濃度と尿沈渣白血球数とを
対比した図面である。FIG. 1 is a diagram comparing the concentration of neutrophil-derived protein in urine with the white blood cell count of urinary sediment.
【図2】尿中好中球由来蛋白濃度と試験紙法の測定結果
とを対比した図面である。FIG. 2 is a diagram comparing the concentration of neutrophil-derived protein in urine with the measurement result of the test strip method.
【図3】日常検体75例について尿中白血球崩壊率の分
布を図示したものである。FIG. 3 is a diagram showing the distribution of leukocyte lysis rate in urine for 75 daily samples.
【図4】尿試料の性状と白血球崩壊率の関係を示す図面
である。FIG. 4 is a drawing showing the relationship between the properties of urine samples and leukolysis rate.
【図5】尿中白血球の崩壊現象について、時間、温度、
及びpHとの関係を図示したものである。FIG. 5: Time, temperature, and
And the relationship with pH.
【図6】尿中白血球崩壊の機序を示す図面である。FIG. 6 is a drawing showing the mechanism of urinary leukocyte breakdown.
【図7】阻害剤による白血球崩壊の阻止の程度を示す図
面である。FIG. 7 is a drawing showing the degree of inhibition of leukolysis by an inhibitor.
【図8】エステラーゼ活性の阻害の程度を示す図面であ
る。FIG. 8 is a drawing showing the degree of inhibition of esterase activity.
【図9】阻害物質の分子量を示す図面である。FIG. 9 is a drawing showing the molecular weights of inhibitors.
【図10】試験紙法に対する阻害物質の検討結果を示す
図面である。FIG. 10 is a drawing showing the results of examination of inhibitors for the test strip method.
【図11】阻害物質を含む尿での白血球に対する試験紙
法の反応特性を示す図面である。FIG. 11 is a drawing showing the reaction characteristics of the test strip method for leukocytes in urine containing an inhibitor.
【図12】ミエロペルオキシダーゼ濃度とラクトフェリ
ン濃度との関係を示す図面である。FIG. 12 is a drawing showing the relationship between myeloperoxidase concentration and lactoferrin concentration.
【図13】MPOの尿中での安定性を示す図面、及び添
加回収試験の結果を示す図面である。FIG. 13 is a drawing showing the stability of MPO in urine and the result of an addition recovery test.
【図14】健常者の尿中MPO値の分布を示す図面であ
る。FIG. 14 is a drawing showing the distribution of MPO values in urine of healthy subjects.
【図15】好中球数とMPO濃度との関係を示す図面で
ある。FIG. 15 is a drawing showing the relationship between the number of neutrophils and MPO concentration.
【図16】1360例についてMPO濃度とLf濃度の
関係を示す図面である。FIG. 16 is a drawing showing the relationship between MPO concentration and Lf concentration for 1360 cases.
【図17】図16の結果を小学5年生以上の群と小学4
年生以下の群にまとめた図面である。FIG. 17 shows the results of FIG. 16 for groups of 5th grade and above and 4th grade.
It is a drawing that is summarized in groups of grades below.
【図18】小学4年以下でLf,MPO≦50ng/m
l、小学5年以上でLf,MPO≦50ng/ml、小
学5年以上でLf≧300ng/ml,MPO/LF<
0.2の3群について、Tf濃度とLf濃度の関係を示
す図面である。FIG. 18: Lf, MPO ≦ 50 ng / m in 4th grade and below
l, Lf, MPO ≤ 50 ng / ml in elementary school 5 years or older, Lf ≥ 300 ng / ml, MPO / LF <in elementary school 5 years or older
It is drawing which shows the relationship of Tf concentration and Lf concentration about three groups of 0.2.
【図19】図18(a)(b)(c)の3群について、
Tf濃度の平均値やt検定結果などを示した図面であ
る。FIG. 19 shows three groups of FIGS. 18 (a) (b) (c),
It is drawing which showed the average value of Tf density | concentration, the t test result, etc.
フロントページの続き (58)調査した分野(Int.Cl.7,DB名) G01N 33/48 - 33/98 Continuation of front page (58) Fields surveyed (Int.Cl. 7 , DB name) G01N 33/48-33/98
Claims (3)
することによって、崩壊白血球も含めて尿中白血球を検
出することを特徴とする、尿路感染症または尿路系炎症
性疾患の検査方法。1. A urinary tract infection or urinary tract inflammation characterized by detecting urinary leukocytes including depleted leukocytes by measuring urinary myeloperoxidase concentration.
Method for sexually transmitted diseases .
ISA法によって尿中ミエロペルオキシダーゼ濃度を測
定することを特徴とする請求項1に記載の尿路感染症ま
たは尿路系炎症性疾患の検査方法。2. An EL using an anti-human polyclonal antibody
The urinary tract infection according to claim 1, wherein the urinary myeloperoxidase concentration is measured by the ISA method.
Or urinary tract inflammatory disease test method .
0ng/ml程度以上を異常値と判定することを特徴と
する請求項1または請求項2に記載の尿路感染症または
尿路系炎症性疾患の検査方法。3. The urinary myeloperoxidase concentration is 25.
The urinary tract infection according to claim 1 or 2, wherein an abnormal value of about 0 ng / ml or more is determined.
Method for testing urinary tract inflammatory disease .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31571394A JP3522865B2 (en) | 1994-11-25 | 1994-11-25 | Urine leukocyte detection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31571394A JP3522865B2 (en) | 1994-11-25 | 1994-11-25 | Urine leukocyte detection method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08145993A JPH08145993A (en) | 1996-06-07 |
| JP3522865B2 true JP3522865B2 (en) | 2004-04-26 |
Family
ID=18068647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP31571394A Expired - Fee Related JP3522865B2 (en) | 1994-11-25 | 1994-11-25 | Urine leukocyte detection method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3522865B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1167970B1 (en) | 1999-03-29 | 2007-02-14 | Asahi Kasei Kabushiki Kaisha | Method for determining a white blood cell count of a whole blood sample |
| WO2002006832A1 (en) * | 2000-07-13 | 2002-01-24 | International Reagents Corporation | Means of examining nephropathy |
| SE0102220D0 (en) * | 2001-06-25 | 2001-06-25 | Pharmacia Diagnostics Ab | Method for estimating the amount of specific cell types |
| JP4814788B2 (en) * | 2004-05-20 | 2011-11-16 | アステラス製薬株式会社 | Test method for interstitial cystitis |
| CN104122395A (en) * | 2013-04-28 | 2014-10-29 | 北京协和洛克生物技术有限责任公司 | Kit for detecting myeloperoxidase (MPO) concentration in sample and preparation method of kit |
| CN118688444B (en) * | 2024-07-05 | 2024-12-20 | 杭州茵菲多组学生物科技有限公司 | Protein marker group for detecting myeloid cells, application, kit and detection method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3087794A (en) | 1960-05-23 | 1963-04-30 | Miles Lab | Chemical test for differentiating leucocytes from erythrocytes |
-
1994
- 1994-11-25 JP JP31571394A patent/JP3522865B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3087794A (en) | 1960-05-23 | 1963-04-30 | Miles Lab | Chemical test for differentiating leucocytes from erythrocytes |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08145993A (en) | 1996-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harper et al. | Risk factors for calculus formation in patients with renal transplants | |
| Koutroubakis et al. | Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease | |
| Harvima et al. | Immunoperoxidase and enzyme-histochemical demonstration of human skin tryptase in cutaneous mast cells in normal and mastocytoma skin | |
| Margulies et al. | Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. | |
| Kobayashi et al. | Conditions for solubilization of Tamm–Horsfall protein/uromodulin in human urine and establishment of a sensitive and accurate enzyme-linked immunosorbent assay (ELISA) method | |
| AU2005203321A1 (en) | Assay | |
| Lauwerys et al. | Preclinical detection of nephrotoxicity: description of the tests and appraisal of their health significance | |
| Liu et al. | Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo | |
| US8012709B2 (en) | Method for determining if a subject having type II diabetes has a kidney disorder | |
| JP3522865B2 (en) | Urine leukocyte detection method | |
| US5073487A (en) | Rapid assay for functional human α1 -proteinase inhibitor | |
| CA2554899C (en) | Method and kit for the measurement of neutrophil cell activation | |
| Ro et al. | Rapid, simple, and reliable method for the diagnosis of CAPD peritonitis using the new MMP‐9 test kit | |
| WO1998005970A1 (en) | Method for examining chronic rejection reactions following organ transplantation and method for determining urine components | |
| Schnebli et al. | Plasma levels of inhibitor-bound leukocytic elastase in rheumatoid arthritis patients | |
| JP5439187B2 (en) | Evaluation of septic patients to determine requirements for therapeutic intervention with anti-inflammatory and / or anticoagulants | |
| Kristjansson et al. | Renal tubular dysfunction after urinary diversion | |
| McCormick et al. | Microtransferrinuria and microalbuminuria: enhanced immunoassay | |
| JP4699631B2 (en) | Urine trypsin inhibitor assay with chelating agent | |
| Billing et al. | Oxidative autoaggression by phagocytes in human peritonitis | |
| JPH0972906A (en) | Differential diagnostic kit of kidney/urinary tract disease | |
| Uttley et al. | Fibrin/fibrinogen degradation products in children with renal disease | |
| Kuźniar et al. | Elastase deposits in the kidney and urinary elastase excretion in patients with glomerulonephritis–evidence for neutrophil involvement in renal injury | |
| Bosch et al. | The antigenic significance and methods of detection of the anti-neutrophil cytoplasmic autoantibodies (ANCA) | |
| RU2181887C2 (en) | Method for determining chronic rejection after kidney transplantation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040205 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090220 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090220 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100220 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100220 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110220 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110220 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120220 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130220 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130220 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140220 Year of fee payment: 10 |
|
| LAPS | Cancellation because of no payment of annual fees |